Should You Buy Xeris Biopharma Holdings, Inc. Stock in 2026?
According to the CirclFi Deep Alpha Valuation Engine, Xeris Biopharma Holdings, Inc. (XERS) scores a robust 7.9/10 on our 32-signal Quality of Company framework. At the current market price of $7.49 and a $1.4B market cap, our analysis maps this fundamental strength against 13 institutional-grade models to determine if a sufficient margin of safety exists.
The short answer: 1 of 8 CirclFi valuation models project upside for Xeris Biopharma Holdings, Inc. (XERS) at $7.49 — the model consensus leans bearish, with a Quality Score of 7.9/10 and Value-Trap risk of 31/100. The full bull case, bear case, and risk factors are below. Educational analysis, not financial advice.
What Is the Investment Case for Xeris Biopharma Holdings, Inc. (XERS) in 2026?
What Is the Bull Case vs the Bear Case for Xeris Biopharma Holdings, Inc. (XERS)?
| Bull case — $8.17 target (+9.1%) | Bear case — $0.59 target (-92.1%) |
|---|---|
| According to the CirclFi Quality of Company (QOC) framework, Xeris Biopharma Holdings, Inc.'s score of 7.9/10 reflects durable competitive advantages that should sustain earnings power through market cycles. | According to the CirclFi Deep Alpha Valuation Engine, the Bayesian DCF model sees the stock as overvalued with a fair value of $0.59 (-92.1%), suggesting that the market price embeds overly optimistic growth assumptions. |
| Industry tailwind: late-stage pipeline catalysts could provide meaningful support for Xeris Biopharma Holdings, Inc.'s revenue and margin trajectory in the Drug Manufacturers - Specialty & Generic space. | According to the CirclFi Deep Alpha Valuation Engine, the wide model spread of +101.2% reflects fundamental divergence on key assumptions (growth, cost of capital) depending on the methodology. |
| Industry headwind: regulatory rejection risk represents a meaningful risk for Xeris Biopharma Holdings, Inc. and its Drug Manufacturers - Specialty & Generic peers. |
How Does XERS Compare to Its Drug Manufacturers - Specialty & Generic Peers?
Valuation data pages: ORGO · HIMS · KNSA · PCRX · AMRX · CRON · DERM · AMLX · GREH · UTHR · AMPH
See full Drug Manufacturers - Specialty & Generic rankings →
Which Other Stocks Score Like XERS on Quality?
Closest companies to XERS’s Quality of Company score of 7.9/10, across all industries.
- LFVN — LifeVantage Corporation (QOC 7.9) · analysis
- HNVR — Hanover Bancorp, Inc. (QOC 7.9) · analysis
- AJG — Arthur J. Gallagher & Co. (QOC 7.9) · analysis
- O — Realty Income Corporation (QOC 7.9) · analysis
- VTMX — Corporación Inmobiliaria Vesta, S.A.B. de C.V. (QOC 7.9) · analysis
- HCKT — The Hackett Group, Inc. (QOC 7.9) · analysis
- NVDA — NVIDIA Corporation (QOC 10.0) · analysis
Which Drug Manufacturers - Specialty & Generic Screens Does XERS Appear In?
So Is Xeris Biopharma Holdings, Inc. (XERS) Worth Buying in 2026?
Our valuation engine sends a clear cautionary signal on Xeris Biopharma Holdings, Inc. at $7.49. 7/8 models flag overvaluation, median fair value sits at $1.36 (-81.8%), and the risk-reward profile appears unfavorable. Quality at 7.9/10 is the one bright spot, but premium quality at the wrong price can still destroy returns. This is a stock where patience — or avoidance — may be the optimal strategy.
These are quantitative model outputs, not investment recommendations. Xeris Biopharma Holdings, Inc.'s future depends on factors — management execution, competitive dynamics, regulatory changes — that no algorithm can fully capture. See all 13 model estimates →
What Else Do Investors Ask About XERS Stock?
Should I buy XERS stock right now?
Based on CirclFi's multi-model analysis, 1 of 8 models see upside for XERS at $7.49. The models are divided, which means the investment case depends heavily on your assumptions about Xeris Biopharma Holdings, Inc.'s future. This is not a buy recommendation — see our full disclaimer.
What are the biggest risks of investing in Xeris Biopharma Holdings, Inc.?
Key risks include: wide model disagreement (1274% spread), signaling high uncertainty; general market and sector-specific risks affecting Drug Manufacturers - Specialty & Generic companies. Always diversify and consult a financial advisor.
How does XERS compare to its competitors?
Among Drug Manufacturers - Specialty & Generic peers, XERS holds a Quality Score of 7.9/10. Comparable companies include ORGO (QOC 8.0), HIMS (QOC 7.8), KNSA (QOC 8.1). The relative ranking helps investors identify whether XERS offers better fundamental quality than alternatives in the same sector.
Is XERS a good long-term investment?
Long-term investment potential depends on fundamental quality and sustainable competitive advantages. XERS's Quality Score of 7.9/10 is encouraging for long-term holders, indicating consistent profitability, manageable debt, and healthy cash flows. Check our full data page for all 13 model estimates.
What price should I buy XERS at?
CirclFi does not provide target buy prices or price alerts. However, our 8 active models produce fair value estimates ranging from $0.59 to $8.17. At $7.49, the stock trades within the range of model estimates. Many value investors look for a 20-30% margin of safety below intrinsic value before buying.
Want the complete picture?
See all 13 model estimates, confidence scores, and the full valuation table for XERS.
Disclaimer: This article is produced by the CirclFi Valuation Engine using quantitative models and is for educational and informational purposes only. It is not financial advice, a buy/sell recommendation, or a solicitation to trade securities. Past performance is not indicative of future results. All data sourced from SEC EDGAR, FRED, and GDELT. Consult a licensed financial advisor before making investment decisions. Full disclaimer →
Buy with Gumroad